Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

(2015) Ming Chang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban

(2014) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis

(2014) Thomas J Velenosi et al.   Expert Opinion on Drug Metabolism & Toxicology

LC–MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column

(2014) Janice Pursley et al.   Bioanalysis

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

(2013) Vijay V. Upreti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

(2013) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

(2012) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Apixaban for Extended Treatment of Venous Thromboembolism

(2012) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

(2010) Zhaoqing Wang et al.   THROMBOSIS AND HAEMOSTASIS

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics

(2008) Hirotaka Tanaka et al.   Clinical and Experimental Nephrology

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION